Skip to main content

Table 1 Biodistribution of 177 Lu-DOTA-chCE7 and 177 Lu-DOTA-control IgG 72 h post RIC injection in nude mice bearing subcutaneous IGROV1 tumours (±PTX)

From: Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model

Organs 177Lu-DOTA-chCE7 177Lu-DOTA-chCE7 + PTX 177Lu-DOTA-control IgG 177Lu-DOTA-control IgG + PTX
Blood 8.9 ± 2.8 6.9 ± 3.5 17.12 ± 3.6 13.3 ± 8.5
Heart 3.9 ± 0.8 3.3 ± 1.4 5.7 ± 2.9 3.9 ± 1.7
Spleen 7.0 ± 2.3 5.7 ± 1.0 5.0 ± 2.8 10.2 ± 6.1
Kidney 2.8 ± 0.3 2.4 ± 0.6 5.4 ± 1.9 4.6 ± 1.8
Stomach 0.4 ± 0.2 0.4 ± 0.1 0.8 ± 0.8 1.0 ± 0.4
Intestine 0.8 ± 0.2 0.7 ± 0.3 1.1 ± 0.3 0.4 ± 0.5
Liver 5.3 ± 1.8 5.7 ± 0.3 5.7 ± 2.5 6.7 ± 1.2
Muscle 0.9 ± 0.2 0.8 ± 0.2 1.1 ± 0.3 1.4 ± 0.6
Bone 1.5 ± 0.2 1.1 ± 0.5 1.9 ± 0.6 2.6 ± 0.5
Tumour 49.6 ± 11.9 45.3 ± 8.6 7.2 ± 2.3 9.1 ± 3.1
  1. Results shown in %IA/g ± SD.